NTGN - Neon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Neon Therapeutics, Inc.

40 Erie Street
Suite 110
Cambridge, MA 02139
United States

Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Mr. Hugh O'DowdPres, CEO & Director688.75kN/A1965
Dr. Eric S. LanderDirector69.71kN/A1957
Dr. Yasir B. Al-WakeelChief Financial Officer529.93kN/A1982
Dr. Richard GaynorPres of R&D536.77kN/A1950
Dr. Edward FritschFounder & CTON/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Neon Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.